Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Seattle Genetics Inc (NASDAQ:SGEN)

Friday’s trading has closed, but SGEN is being traded in the after-hours session. After-Hours quote »
47.87
Delayed Data
As of 3:59pm ET
 +0.53 / +1.12%
Today’s Change
30.05
Today|||52-Week Range
52.33
+48.99%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.9B

Company Description

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. ADCETRIS is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Contact Information

Seattle Genetics, Inc.
21823 30th Drive SE
Bothell Washington 98021
P:(425) 527-4000
Investor Relations:
(425) 527-4160

Employees

Shareholders

Other institutional53.95%
Mutual fund holders50.84%
Individual stakeholders35.76%

Top Executives

Clay B. SiegallChairman, President & Chief Executive Officer
Eric L. DobmeierChief Operating Officer
Todd E. SimpsonChief Financial Officer
Vaughn B. HimesEVP-Process Sciences & Technical Operations
Jonathan DrachmanChief Medical Officer, EVP-Research & Development